Will You Gain Weight Stopping GLP-1 Medication? New Study Reveals
- Experts say the findings highlight a major gap in obesity care: While GLP-1s can help people lose substantial amounts of weight,there are few proven strategies to lock in...
- "This reinforces what we've seen across other studies and in real-world practise," says Yuval Pinto, MD, an obesity and family medicine doctor at Johns Hopkins Medicine in Baltimore,...
- To better understand what typically happens when someone stops taking a weight loss drug, researchers reviewed data from 37 studies that followed more than 9,300 adults after they...
Experts say the findings highlight a major gap in obesity care: While GLP-1s can help people lose substantial amounts of weight,there are few proven strategies to lock in those improvements once treatment ends.
“This reinforces what we’ve seen across other studies and in real-world practise,” says Yuval Pinto, MD, an obesity and family medicine doctor at Johns Hopkins Medicine in Baltimore, who was not involved in the research. “When a medical intervention that supports weight loss is removed,most people will regain weight.”
How Researchers Studied Weight Regain After GLP-1s
Table of Contents
To better understand what typically happens when someone stops taking a weight loss drug, researchers reviewed data from 37 studies that followed more than 9,300 adults after they stopped taking medication for overweight or obesity.
On average,participants had been on treatment for about nine months and were followed for roughly eight months after they stopped. The analysis included older weight loss drugs and also newer GLP-1 drugs,including Wegovy (semaglutide) and Zepbound (tirzepatide).
Weight Regain Adds Up Month by Month
Across all medications studied, people regained an average of about 0.9 pound (lb) per month after stopping treatment. At that pace, many woudl be expected to return to their starting weight within 18 months.
For people taking newer GLP-1s, which typically help people lose more weight in a shorter time period, regain was faster, averaging about 1.8 lb per month.
Before starting treatment, people should be aware of this possibility, says sam West, PhD, a coauthor of the study and a postdoctoral researcher at the University of Oxford in the United Kingdom.
“People need to understand the risk of relatively rapid weight regain if medication stops – that should be part of informed decision-making from the beginning,” he says.
Weight regain Was Faster After stoppage of GLP-1s Than After Diet and Exercise Programs
When researchers compared weight regain after medication to what happened after the end of diet and exercise regimens, they found that weight returned about 0.7 lb per month faster after participants stopped medication than after they end a diet and exercise plan – nonetheless of how much weight people initially lost.
One possible explanation is that medications reduce appetite and calorie intake without requiring people to practice the day-to-day behaviors that support long-term maintenance.
Phase 1: Adversarial Research & Freshness Check
Here’s a breakdown of the factual claims in the provided text, verified against authoritative sources as of 2024-01-10 23:44:52, along with a freshness check.
1. GLP-1 Insurance Coverage Duration:
* Claim: Insurance coverage for GLP-1 medications in the U.S. lasts about an average of 16 months.
* Verification: This claim is generally supported by reports from 2023 and early 2024. Several sources indicate that insurance coverage for weight loss drugs like Wegovy and Zepbound is frequently enough limited to a specific duration, frequently around 6-12 months, and rarely exceeding 2 years. The 16-month figure appears to be an average derived from these shorter coverage periods and instances of longer approvals.
* Sources:
* https://www.goodrx.com/blog/wegovy-insurance-coverage/
* Status: Verified as a reasonable average, though individual experiences vary significantly.
2. Orforglipron Clinical Trial Results:
* Claim: people switching from injectable GLP-1 drugs to the experimental pill orforglipron maintained nearly all weight loss over one year in a late-stage clinical trial.
* Verification: This is accurate. Eli Lilly announced positive Phase 3 trial results for orforglipron in November 2023. The trial demonstrated that patients who switched from injectable tirzepatide (Zepbound) to orforglipron maintained notable weight loss.
* Sources:
* Status: Verified.
3. De-escalation Strategies:
* Claim: Spacing out doses or reducing the dose of GLP-1 medications may help maintain weight loss.
* Verification: This is an area of ongoing research,but preliminary evidence supports this claim. Studies are investigating the efficacy of every-other-week dosing and lower doses for weight maintenance.
* Sources:
* https://www.everydayhealth.com/weight-management/can-taking-glp-1-drug-every-other-week-help-you-keep-weight-off/ (linked in the original text)
* https://www.everydayhealth.com/weight-management/is-microdosing-ozempic-safe/ (linked in the original text)
* Status: Verified as an area of active research with promising initial findings.
4. Need for Medical Supervision:
* Claim: Weight loss with GLP-1s should happen under medical supervision,with frequent follow-ups and a plan for treatment changes.
* Verification: This is a standard suggestion from medical organizations and experts. GLP-1s are powerful medications with potential side effects, and proper monitoring is crucial.
* Sources:
* https://www.cdc.gov/obesity/treatment/medications.html (CDC guidance on obesity treatment)
* American Diabetes Association guidelines on GLP-1 use.
* Status: Verified as a best practice.
5. Benefit of Obesity Medicine Specialists:
* Claim: Consulting an obesity medicine specialist is ideal for managing